In contrast to the thiazolidinediones, antidiabetic drugs that act by binding to and activating PPAR-γ, which improve insulin sensitivity by mechanisms which may involve increase in adiponectin [29], treatment with niacin often causes increased glucose levels and insulin resistance. The gene discussed is ADIPOQ; the disease is Insulin resistance.